Online ISSN: 2149-3189
2015
Monthly
Nicaea Medical Publishing
Türkiye

Experience of thrombotic microangiopathy unresponsive to therapeutic apheresis

Hilmi Erdem Sümbül, Onur Taktakoğlu
DOI
https://doi.org/10.18621/eurj.389830
Abstract
No abstract available.
Keywords
plasmapheresis, rituximab, thrombotic microanjiopathy
References

[1] George JN. How I treat patients with thrombotic thrombocytopenic purpura:2010. Blood 2010;116:4060-9.

[2] Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patient with thrombotic thrombocytopenic purpura. Blood 2010;115:1500-11.

[3] George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006;21:49-56.

[4] Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 2009;84:418-21.

[5] McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmakonetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010;8:1201-8.

How to Cite
1.
Sümbül HE, Taktakoğlu O. Experience of thrombotic microangiopathy unresponsive to therapeutic apheresis. Eur Res J. 2019;5(1):233-235. doi:10.18621/eurj.389830
License
Creative Commons License

Copyright (c) 2019 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

View Vol. 5 No. 1 (2019)

Vol. 5 No. 1 (2019)

Article Information

  • Article Type Letter to the Editor
  • Submitted February 21, 2026
  • Published January 3, 2019
  • Issue Vol. 5 No. 1 (2019)
  • Section Letter to the Editor
  • File Downloads 1080
  • Abstract Views 220
  • Altmetrics
  • Share
Download data is not yet available.